Molbio Diagnostics Limited will host a virtual group meeting with investors and analysts on September 22, 2026. The session is scheduled to begin at 11:00 am IST and will focus on the company's general business outlook.

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that no unpublished price-sensitive information (UPSI) will be shared during the interaction.

Meeting Details

The event is structured as a group meeting for investors and analysts. All discussions will rely solely on information already available in the public domain.

Regulatory Compliance

Darshan Raghunath Karekar, Company Secretary & Compliance Officer, issued the intimation on September 17, 2026. The schedule remains subject to change due to exigencies on either side. The disclosure is also available on the company's website.

Molbio Diagnostics reported a consolidated net profit of ₹52.7 crore for the quarter ended June 30, 2026, marking a significant turnaround from a loss of ₹23.9 crore in the corresponding period of FY25. The diagnostics manufacturer’s results reflect robust revenue growth following its recent public listing, with total income rising to ₹411.5 crore from ₹100.5 crore a year earlier.

The Board of Directors approved the unaudited standalone and consolidated financial results on September 5, 2026. Standalone total income was recorded at ₹400.7 crore, compared to ₹96.8 crore in the prior year quarter. The company highlighted that certain export orders pertaining to Q4FY26, amounting to approximately ₹57 crore, were deferred due to the prevailing situation in the Gulf and were subsequently recognized in Q1FY27.

Financial Performance

The group reported a consolidated EBITDA of ₹103.7 crore, against a loss of ₹14.5 crore in Q1FY25, with an EBITDA margin of 25.2% compared to (14.4%) previously. Standalone net profit for the quarter was ₹56.6 crore, up from a loss of ₹13.4 crore in Q1FY25. Basic and diluted earnings per share (EPS) for the consolidated entity were ₹5.21, compared to a loss of ₹2.10 per share in Q1FY25. For the standalone entity, EPS was ₹5.02, against a loss of ₹1.19 per share in the prior year quarter. The comparative figures for Q1FY25 have been retrospectively adjusted for a 4:1 bonus issue allotted in September 2025.

During the earnings call, management disclosed that the company sold 164 devices and 62.4 lakh kits in Q1FY27. Export revenue stood at approximately ₹67 crore, or 16% of total revenue from operations, including the catch-up of deferred orders. Management noted that trailing 12-month receivable days remained stable at 87 days in June versus 86 days in March, while inventory days improved to 230 days from 280 days.

What the Numbers Show

The sharp improvement in profitability is largely attributable to the recognition of deferred revenue. Management noted that export orders worth approximately ₹57 crore from Q4FY26 were pushed into Q1FY27 due to disruptions in the Gulf region. This one-time catch-up effect significantly boosted the top line, which grew more than fourfold YoY. Despite the volume surge, the company maintains that its business has a non-linear revenue profile, advising investors to assess performance on a full-year basis. Additionally, the company entered FY27 with meaningful capacity headroom, with FY26 device and test-kit utilization at 42% and 58% respectively, positioning it for volume-led scale-up without near-term incremental capex.

Management provided further clarity on the revenue mix, stating that ₹399 crore of the consolidated revenue came from Molbio’s core operations, with approximately ₹11 crore contributed by subsidiary Prognosys Medical Systems. OptraScan’s contribution remains minuscule as it is in the early stages of commercialization. For the full year, Prognosys is expected to deliver margins closer to 19% EBITDA, while OptraScan is not expected to be profitable in FY27. Management guided for top-line growth of roughly 25% for the year and an EBITDA margin of 24% to 25%.

Corporate Developments

Subsequent to the quarter ended June 30, 2026, Molbio Diagnostics completed its Initial Public Offer (IPO). The issue comprised 11,646,246 equity shares, including a fresh issue of 2,480,246 shares aggregating to ₹2,000.00 million and an offer for sale by existing shareholders aggregating to ₹7,396.96 million. The shares were listed on the NSE and BSE on August 17, 2026, at an issue price of ₹807 per share for investors and ₹731 for employees. Deployment of the net issue proceeds is underway across capex for automation and building an R&D facility in Bengaluru. Management clarified that of the ₹200 crore raised, approximately ₹72 crore will be allocated to automation and about ₹105 crore to build an integrated R&D center in Bengaluru.

During the quarter, the company increased its stake in Prognosys Medical Systems Private Limited (PMS) from 65.47% to 70.00% by acquiring an additional 4.53% stake. Earlier in FY26, Molbio had converted its associate interest in OptraSCAN Inc. into a subsidiary by increasing its holding to 60%, effective November 1, 2025. OptraScan recently received US FDA clearance for its end-to-end digital pathology solution, including hardware, software, and AI, in July 2026. Management stated that conversations have begun with large laboratory chains in the US, with meaningful financial contribution expected from FY28 onwards.

Regulatory and Tax Matters

The company disclosed an ongoing survey under Section 133A of the Income-tax Act, 1961. The tax department has raised demands aggregating to ₹208.71 million plus interest and penalty for assessment years 2020-21 to 2024-25. Molbio has appealed to the Commissioner of Income Tax (Appeals) and paid ₹78.95 million under protest as of June 30, 2026. Management expressed confidence in a favorable outcome and made no adjustments in the financial results.

Additionally, the board authorized Key Managerial Personnel (KMPs), including CEO Sriram Natarajan and CFO Manan Bimal Khokhani, to determine the materiality of events for disclosure under SEBI Listing Regulations.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE869T01028/8fdc6274-ddca-4a9b-a736-3de7d20746b5.pdf